Boehringer Ingelheim Pharma GmbH & Co. KG

Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance (2021) Schumann T, König J, von Loeffelholz C, Vatner DF, Zhang D, Perry RJ, Bernier M, et al. Journal article Immunocompetent cancer-on-chip models to assess immuno-oncology therapy (2021) Maulana TI, Kromidas E, Wallstabe L, Cipriano M, Alb M, Zaupa C, Hudecek M, et al. Journal article, Review article PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Conference contribution DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE (2021) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis (2021) Mayer AL, Scheitacker I, Ebert N, Klein T, Amann KU, Daniel C Journal article Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. (2021) Ntaios G, Huisman M, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, et al. Journal article Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. (2021) Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airo P, Ananieva LP, Czirjak L, et al. Journal article The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. (2021) Wollin L, Trinh MT, Zhang Y, Distler J Journal article The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease (2021) Wollin L, Trinh MT, Zhang Y, Distler J Journal article Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial (2021) Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Journal article